• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
157902 162 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  : L+ ]9 X1 u% K6 G2 \

- w' c# Z8 }/ X  L3 D
2 ?- x' J/ h1 o; l. zSub-category:; r9 j2 T4 `7 a6 I8 _1 O
Molecular Targets % a3 s4 t4 ^: \- ~& S, t6 z
" a* Z- ^& R" U" B$ x- T1 a4 r" Z
1 f- c5 H& \) {9 B$ w+ U
Category:$ h* A1 A5 P! ^- ]
Tumor Biology $ x6 k" h! _% b" L# U% Q1 f; s
# l% X2 x4 L7 E5 ]2 E1 ]
3 h/ e& W; m+ D/ T$ _- f
Meeting:
- i7 _9 s# {  m( Y+ w! W2011 ASCO Annual Meeting
6 `8 J* n- f4 j$ g# ~# x6 D4 S& H. c! b/ E$ C* n. T# s1 P) N
8 [; ?, W! q: j5 t
Session Type and Session Title:6 O  f) @% n- K" ]: i1 I8 q7 ]
Poster Discussion Session, Tumor Biology
$ N5 ?* v* F" C  {- R
3 c9 p$ g& W, {" K1 ?% s; i' d5 k& H8 x
Abstract No:; q, `; b( M& _% h6 Y; x
10517
& G2 y3 Z+ c' T4 N. j) p
/ M3 C! _6 o' d
; M: S  e5 @- |* X& NCitation:
& N* ?/ @& Z7 \# i- TJ Clin Oncol 29: 2011 (suppl; abstr 10517)
  p: z# ~* A2 j4 C+ u+ Z# j* ~
6 P8 U3 N3 f! M4 ^9 C9 }. R, Z. W  `' k
Author(s):* g9 q9 l6 h. ^+ ]4 Z( z0 v
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 4 k  a6 D/ e/ {  S/ u' x

9 S3 ?! z" i( c# v0 U' w6 a5 k
( t# z0 X  {1 d
8 k- Y" K% Q$ \! i& ~  ~' wAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
/ |, |/ w% S9 M! D3 C6 c
1 Z/ @/ i7 h/ s6 h. nAbstract Disclosures! m7 I  v# N+ H

. Z1 ^5 l% U4 h, V- vAbstract:/ e$ v! t; E! r% w

3 Y* Y# [3 y* C3 @
$ N2 K+ Y- ^9 W% S, F  ]; _Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
9 y, [; B0 e- R9 ]4 r6 N& [; o3 l9 e; [$ X9 P* l* C% c& A
6 W; i5 m% E8 d1 [
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 ; K& t+ Q" I  J# s
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

) y& Q3 w, Y) c/ C& F; I; |化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
4 {" Z2 U/ T5 C7 b& Q5 f! k& D易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
' e/ y0 N; {% ^4 EALK一个指标医院要900多 ...
0 |1 f, S- A3 {; B
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?' z- {# Q. H% E3 p; c# R
" w2 u3 A* o4 v- Y
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表